Dorsey Wright & Associates Genmab A/S Transaction History

Dorsey Wright & Associates

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$33.8 - $47.06 $2.96 Million - $4.12 Million	87,451 New	87,451 $3.71 Million
Q1 2022 Apr 27, 2022	SELL	$30.95 - $39.68 $3.29 Million - $4.22 Million	-106,239 Closed	0 $0
Q4 2021 Jan 27, 2022	SELL	$35.87 - $47.12 $160,374 - $210,673	-4,471 Reduced 4.04%	106,239 $4.2 Million
Q3 2021 Oct 26, 2021	BUY	$41.55 - $48.72 $4.6 Million - $5.39 Million	110,710 New	110,710 $4.84 Million
Q1 2021 Apr 27, 2021	SELL	$30.92 - $44.4 $2.62 Million - $3.76 Million	-84,674 Closed	0 $0
Q4 2020 Jan 28, 2021	SELL	$33.66 - $40.76 $61,530 - $74,509	-1,828 Reduced 2.11%	84,674 $3.44 Million
Q3 2020 Oct 28, 2020	BUY	$33.07 - $38.68 $38,592 - $45,139	1,167 Added 1.37%	86,502 $3.17 Million
Q2 2020 Jul 23, 2020	BUY	$20.05 - $33.89 $1.71 Million - $2.89 Million	85,335 New	85,335 $2.86 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Dorsey Wright & Associates, based on Form 13F filings with the SEC.

Stay updated on Dorsey Wright & Associates with notifications on news.